M G Castagna1, R Forleo2, F Maino2, N Fralassi2, F Barbato2, P Palmitesta3, T Pilli2, M Capezzone2, L Brilli2, C Ciuoli2, S Cantara2, C Formichi2, F Pacini2. 1. Department of Medical, Surgical and Neurological Sciences, University of Siena, Siena, Italy. m.g.castagna@ao-siena.toscana.it. 2. Department of Medical, Surgical and Neurological Sciences, University of Siena, Siena, Italy. 3. Department of Social, Political and Cognitive Sciences, University of Siena, Siena, Italy.
Abstract
PURPOSE: According to American Thyroid Association (ATA) guideline, papillary thyroid cancer (PTC) with minimal extrathyroidal extension (mETE) is classified at "intermediate risk" of persistent/recurrent disease. However, the impact of mETE per se on patients' outcome is not fully understood. The aim of our study was to evaluate the prognostic significance of mETE in patients with PTC not submitted to therapeutic or prophylactic lymph node dissection, according to tumor size and other prognostic factors. PATIENTS AND METHODS: We retrospectively evaluated a total of 514 PTC patients: 127 (24.7%) had mETE (pT3Nx) and 387 (75.3%) had negative margins (pT1-2Nx). At a median follow-up of 9.1 years, patients were divided in two groups: patients with "good outcome" (no evidence of disease) and patients with "poor outcome" (persistent structural disease or recurrent disease or tumor-related death). RESULTS: The rate of patients with "poor outcome" was significantly higher in patients with mETE compared with patients with negative margins (11.8 versus 5.1%; OR 2.4576, 95% CI 1.2178-4.9594, p = 0.01). However, mETE was significantly associated with poor outcome only in patients with tumors larger than 1.5 cm. CONCLUSIONS: mETE is an unfavorable prognostic factor in tumors larger than 1.5 cm, suggesting that, in the absence of other unfavorable characteristics, smaller tumors with mETE should be classified and managed as "low risk" tumors.
PURPOSE: According to American Thyroid Association (ATA) guideline, papillary thyroid cancer (PTC) with minimal extrathyroidal extension (mETE) is classified at "intermediate risk" of persistent/recurrent disease. However, the impact of mETE per se on patients' outcome is not fully understood. The aim of our study was to evaluate the prognostic significance of mETE in patients with PTC not submitted to therapeutic or prophylactic lymph node dissection, according to tumor size and other prognostic factors. PATIENTS AND METHODS: We retrospectively evaluated a total of 514 PTC patients: 127 (24.7%) had mETE (pT3Nx) and 387 (75.3%) had negative margins (pT1-2Nx). At a median follow-up of 9.1 years, patients were divided in two groups: patients with "good outcome" (no evidence of disease) and patients with "poor outcome" (persistent structural disease or recurrent disease or tumor-related death). RESULTS: The rate of patients with "poor outcome" was significantly higher in patients with mETE compared with patients with negative margins (11.8 versus 5.1%; OR 2.4576, 95% CI 1.2178-4.9594, p = 0.01). However, mETE was significantly associated with poor outcome only in patients with tumors larger than 1.5 cm. CONCLUSIONS: mETE is an unfavorable prognostic factor in tumors larger than 1.5 cm, suggesting that, in the absence of other unfavorable characteristics, smaller tumors with mETE should be classified and managed as "low risk" tumors.
Authors: Wouter P Kluijfhout; Jesse D Pasternak; Julie S Kwon; James Lim; Wen T Shen; Jessica E Gosnell; Elham Khanafshar; Quan-Yang Duh; Insoo Suh Journal: Ann Surg Oncol Date: 2015-12-01 Impact factor: 5.344
Authors: Nimmi Arora; Harma K Turbendian; Theresa Scognamiglio; Patrick L Wagner; Stanley J Goldsmith; Rasa Zarnegar; Thomas J Fahey Journal: Surgery Date: 2008-12 Impact factor: 3.982
Authors: F Pacini; E Brianzoni; C Durante; R Elisei; M Ferdeghini; L Fugazzola; S Mariotti; G Pellegriti Journal: J Endocrinol Invest Date: 2015-08-12 Impact factor: 4.256
Authors: R Forleo; N Fralassi; F Maino; M Capezzone; L Brilli; T Pilli; S Cantara; M G Castagna Journal: J Endocrinol Invest Date: 2020-05-09 Impact factor: 4.256
Authors: Robert Seifert; Michael Andreas Schäfers; Barbara Heitplatz; Laura Kerschke; Burkhard Riemann; Benjamin Noto Journal: J Nucl Med Date: 2021-03-26 Impact factor: 11.082